EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

TPS42 - Allergen immunotherapy 4

Saturday 01 Jun, 12:00 PM - 13:00 PM Valencia, Spain
Poster Zone Thematic Poster Session
Allergen-specific immunotherapy based on purified and modified Fel d 1 allergen from cat dander
An interim analysis of a multi-center, oPEn label, Randomized study to investigate the saFEty of an optimal acCelerated scheme for immunoTherapy in adolescent and adult patients with moderate to severe AR with or without asthma in China. (PERFECT)
Application of allergen standardization in allergen-specific immunotherapy (AIT)
Clinical and immunological comparison between two subcutaneous immunotherapy products in children with allergic rhinitis
Evaluating the relevance of measurement tools in assessing the effectiveness of 12 SQ HDM SLIT-tablet for Chinese patients with moderate to severe house dust mite allergic rhinitis with or without allergic asthma: a prospective observational study
Evaluation of auditory function in children with allergic rhinitis treated with specific immunotherapy
Immunological changes induced by a salsola kaly extract in patients with allergic rhinitis or rhinitis and asthma
Is the use of anti-hypertensive medication safe during hymenoptera venom immunotherapy?
Real-life Non-interventional Post authorization Safety Study with the SQ tree sublingual immunotherapy tablet
Role of sublingual immunotherapy in management of patients with moderate to severe allergic rhinitis; one year study
Safety and Tolerability of Rush Updosing Using a Mugwort Allergoid Extract for Subcutaneous Allergen Immunotherapy
Sublingual dust mite allergen immunotherapy reduces respiratory infections in children with allergic rhinitis
Treatment satisfaction and health literacy among patients undergoing allergen-specific immunotherapy -Data from a tertiary allergy centre
Using the AllergyVax app to increase adherence to allergen subcutaneous immunotherapy